多西他赛+顺铂化疗联合同期手术治疗在冠心病合并肺癌患者中的应用效果分析  

Eff ect Analysis of Docetaxel Plus Cisplatin Chemotherapy Combined with Concurrent Surgery in Patients with Coronary Heart Disease Complicated with Lung Cancer

作　　者：张忠晓[1] 张红 陈德才 ZHANG Zhong-xiao;ZHANG Hong;CHEN De-cai(Department of Hepatobiliary,Pancreatic a n d Splenic Surgery,Nanyang First People’s Hospital,Nanyang 473000,China;Department of Hepatobiliary,Pancreatic and Splenic Surgery,Zhengzhou Seventh People’s Hospital,Zhengzhou 450016,China)

机构地区：[1]南阳市第一人民医院血管外科,南阳473000 [2]郑州市第七人民医院血管外科,郑州450016

出　　处：《中国合理用药探索》2022年第10期57-62,共6页Chinese Journal of Rational Drug Use

基　　金：河南省卫生健康委医学科技攻关计划联合共建项目(LHGJ20191120)。

摘　　要：目的:分析多西他赛+顺铂化疗联合同期手术治疗在冠心病合并肺癌患者中的应用效果分析。方法:选取2017年2月~2019年2月于本院接受治疗的冠心病合并肺癌患者108例,按照入院单双号分为观察组和对照组,每组54例。对照组仅进行同期冠状动脉旁路移植术联合肺癌切除术治疗,观察组在同期手术治疗的基础上联合多西他赛+顺铂化疗。比较两组患者治疗前后的肿瘤标记物水平、T淋巴细胞亚群水平变化,并评价两组的疾病控制率、生存率及安全性。结果:治疗后,两组鳞癌相关抗原(SCC)、癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)水平均降低,且观察组低于对照组(P<0.05);治疗后,两组T淋巴细胞亚群(CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+))水平均下降,观察组高于对照组(P<0.05);观察组的疾病控制率(79.63%)高于对照组(61.11%,P<0.05);观察组的术后6个月、1年和3年的生存率均高于对照组(P<0.05),且并未出现明显的化疗毒性。结论:在同期手术治疗的基础上联合多西他赛+顺铂化疗能有效改善冠心病合并肺癌患者的肿瘤标记物水平,提高机体免疫功能,提高其近期及远期生存率,且临床疗效较好,安全性较高,值得临床推广应用。Objective:To analyze the application eff ect of docetaxel plus cisplatin chemotherapy combined with concurrent surgery in patients with coronary heart disease complicated with lung cancer.Methods:A total of 108 patients with coronary heart disease complicated with lung cancer treated in our hospital from February 2017 to February 2019 were divided into the observation group and the control group according to the odd-even number of admission,54 cases in each group.The control group was only treated with concurrent coronary artery bypass grafting combined with lung cancer resection,while the observation group was treated with docetaxel combined with cisplatin chemotherapy before operation.The levels of tumor markers and T lymphocyte subsets before and after treatment were compared between the two groups,and the disease control rate,survival rate and safety of the two groups were evaluated.Results:After treatment,the levels of squamous cancinoma-associated antigen(SCC),carcinoembryonic antigen(CEA)and cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)in the two groups were decreased,and the observation group was signifi cantly lower than the control group(P<0.05).After treatment,the levels of T lymphocyte subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))in the two groups were decreased,but the observation group was signifi cantly higher than the control group(P<0.05).The disease control rate of the observation group was 79.63%,which was signifi cantly higher than that of the control group(61.11%,P<0.05).The 6-month,1-year and 3-year survival rates of the observation group were higher than those of the control group(P<0.05),and there was no obvious chemotherapy toxicity.Conclusion:Combined with docetaxel and cisplatin chemotherapy on the basis of concurrent surgical treatment can eff ectively improve the level of tumor markers in patients with coronary heart disease complicated with lung cancer,improve the immune function of the body,improve the short-term and long-term survival rate,and has good clinical effi cacy and high saf

关 键 词：冠心病合并肺癌 多西他赛 顺铂 肿瘤标记物 免疫功能 生存率 

分 类 号：R541[医药卫生—心血管疾病]